AVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avalo Therapeutics Inc (AVTX) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite bullish analyst ratings and hedge fund interest, the company's poor financial performance, lack of recent news catalysts, and mixed technical indicators suggest caution. The stock may be worth monitoring for future developments, but it does not currently align with the user's investment strategy.
The MACD is positive at 0.388 but contracting, indicating weakening momentum. RSI is neutral at 56.794, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels (Pivot: 16.545, R1: 18.655). However, the regular market price dropped by -4.25%, showing short-term weakness.
Analysts have initiated coverage with high price targets ($39 and $
and positive outlooks for the company's lead program AVTX-009, which is projected to achieve significant sales if approved.
Hedge funds are heavily buying, with an 829.12% increase in buying activity over the last quarter.
The company's financials are extremely weak, with a 100% revenue drop, a net income loss of -$30.63M (down -660.69% YoY), and negative EPS of -2.
No recent news or event-driven catalysts to support a bullish case.
The stock's regular market price dropped by -4.25%, reflecting bearish sentiment.
The company's financial performance in Q3 2025 was poor, with revenue dropping to $0 (-100.00% YoY), net income falling to -$30.63M (-660.69% YoY), and EPS declining to -2.19 (-22.61% YoY). Gross margin also dropped to 0 (-100.00% YoY), indicating significant financial instability.
Analysts are bullish on AVTX. Guggenheim initiated coverage with a Buy rating and a $50 price target, citing the potential of AVTX-009 in treating hidradenitis suppurativa and projecting $2.1B in peak global sales. Mizuho also initiated coverage with an Outperform rating and a $39 price target, expecting positive Phase II data in mid-2026 to drive share outperformance.
